Reports Q4 revenue $23.8M, consensus $23.01M."We are very pleased with the results we delivered in 2022 and continue to see positive adoption heading into 2023," said Reza Zadno, Chief Executive Officer. "We believe there are several positive factors we have seen that will allow us to continue to execute against our strategic growth plan in 2023, including an expanded field based commercial team, increased surgeon and patient interest, and having secured contracts with many of the large IDNs. We believe these catalysts will further the adoption of our technology to become the standard of care for BPH."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRCT:
